Stockchase Opinions

Brianne Gardner Medtronic Inc MDT-N SELL ON STRENGTH Aug 28, 2023

Ugly chart. Street opinion is a blend of Buy and Hold at these levels. She waits to see a trend reversal before getting in. Fundamentally, 9/10. Diverse portfolio, likes the positioning. Healthcare is great before a recession, but better names out there. Ride it out until you can break even.

(Analysts’ price target is $94.00)
$81.140

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

PAST TOP PICK
(A Top Pick Sep 01/23, Up 3%)

It has neuroscience products, robotic surgery products, etc. People are getting back into having surgeries so it can raise prices. He is looking for better returns in the next while.

COMMENT
Is one of the biggest beneficiaries of partnering with Nvidia

They partner with Nvidia aggressively, as in MDT's effective colonoscopy machine.

BUY

They use AI in their medical devices; have lots of good devices.

BUY
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

MDT is a mature MedTech company that is now trading at a 15.9x Forward P/E. Over the last few years, MDT’s valuation has ranged from 13.4x to 22.8x Forward P/E, we think the current valuation is fairly attractive. MDT’s share price has performed well recently due to a combination of 1) investors moving to defensive sectors with stable cash flows 2) MDT reported very solid earnings with a 5.3% organic growth rate.
Unlock Premium - Try 5i Free

BUY
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

MDT is a mature MedTech company that is now trading at a 15.9x Forward P/E. Over the last few years, MDT’s valuation has ranged from 13.4x to 22.8x Forward P/E, we think the current valuation is fairly attractive. MDT’s share price has performed well recently due to a combination of 1) investors moving to defensive sectors with stable cash flows 2) MDT reported very solid earnings with a 5.3% organic growth rate.
Unlock Premium - Try 5i Free

BUY

They just delivered a fantastic quarter recently and has rallied 6% since then as the market rotates to healthcare.

HOLD

Lots of development can happen in the area of medical devices. Great business. Keeps people out of hospitals. These companies should do well over the next while, as medical solutions move away from being drug-centred. Prefers SYK.

DON'T BUY

It's gone from a market darling to loser, trading at a 10-year low now. It's a show-me stock, though cheap at 15x PE. If the company can grow 5%, maybe it's worth buying. They need to work out some issues first.

BUY

Well-managed. She likes this sector, medical devices, becuse procedures are picking up, and aging demographics are another tailwind.

BUY

It's been lost in the wilderness for years, but has had a bunch of successful product launches and the stock is now cheap.